Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have received an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $56.57.

A number of equities analysts have commented on AGIO shares. Royal Bank of Canada upped their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. Scotiabank upped their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of AGIO. Atria Investments Inc lifted its position in Agios Pharmaceuticals by 47.4% during the third quarter. Atria Investments Inc now owns 10,628 shares of the biopharmaceutical company’s stock valued at $472,000 after acquiring an additional 3,418 shares during the last quarter. Quest Partners LLC lifted its position in Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $892,000. Charles Schwab Investment Management Inc. lifted its position in Agios Pharmaceuticals by 1.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 465,620 shares of the biopharmaceutical company’s stock valued at $20,687,000 after acquiring an additional 8,093 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its position in Agios Pharmaceuticals by 20.5% during the third quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock valued at $38,002,000 after acquiring an additional 145,416 shares during the last quarter.

Agios Pharmaceuticals Trading Up 3.3 %

Shares of NASDAQ:AGIO opened at $32.71 on Friday. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 2.88 and a beta of 0.90. Agios Pharmaceuticals has a 12 month low of $27.14 and a 12 month high of $62.58. The firm’s 50-day moving average is $33.44 and its 200 day moving average is $41.43.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, equities analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.